Latest From Biotech Now

BIO 2013 Pacific Rim Summit Ends with a Look at Natural Gas

Pac_Rim115x75

This year marked the first time in the event’s eight year history that it was held in California. With 400 attendees present, BIO’s 2013 Pacific Rim Summit had a record number of exhibitors, poster presenters, and media present. BIO concluded its summit with a robust plenary titled, The Golden Age of Gas, moderated by Jonathan Burbaum, Program Director at ARPA-E, panelists consisted of the Laurel Harmon, VP of Government Relations, Lanzatech, Alan Shaw, Chairman of the Board, Read More >

Environmental & Industrial  |  Leave a comment  |  Email This Post
Tags: , , , , ,

What’s Behind the Biotech IPO Boom?

BIOtech-stocks

Everyone knows that it’s been a knock-out year for the biotech sector in the public markets, which includes a large and well-performing IPO class. So far in 2013, 39 US-based companies have gone public, five European-based companies, and one Canadian company. Of these 45 IPOs, 42 companies have gone public on US stock exchanges. That’s over double the amount we saw in 2012. This year’s IPOs have also been successful at raising the amount of money Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Fewer Small Public Biotechs Today

Fig2-size-2008-vs-2013-115x76

A lot can happen in six years. The number of active biotech companies currently trading on US exchanges is now only 300. At the start of 2008, there were almost 400 active companies.   The net decrease in the number of active companies since 2008 is 24%. Had it not been for all the IPO activity we have seen this year, the decrease would have been substantially more. In fact, only 55% of the original Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

VIDEO: Public Policies to Promote the Innovation Economy

SBIR Reauthorization Moves Forward

What can lawmakers do to make the US more competitive globally and encourage investment in groundbreaking R&D companies? Earlier today, the Coalition of Small Business Innovators held a forum at the National Press Club to discuss proposals that would do just that. Moderated by Paul Stimers, a partner with K&L Gates, the panel included Doug Doerfler, president and CEO of MaxCyte, Ed Mathers, a partner with venture capital firm New Enterprise Associates, Katherine Hamilton, policy Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

FDA Check-Up: Drug Development and Manufacturing Challenges

Paul Hastings

I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current company, OncoMed Pharmaceuticals, is working at the cutting edge of oncology research, focused on antibodies that target a specific set of cells within tumors, known as tumor initiating cells, that drive the growth of the tumor and can differentiate into various cell types within the tumor. Currently, we have five products in clinical development in over 13 completed or ongoing Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,